Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Launched by UNIVERSITY OF COLORADO, DENVER · Sep 2, 2022
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Obese youth with and without Type 2 Diabetes + lean controls who were previously enrolled in the Renal HEIR Study
- • Participants who will undergo a PET Scan: ≥ 18 years
- Exclusion Criteria:
- • Anemia
- • Seafood, iodine, or penicillin allergy
- • Pregnancy
- • MRI Scanning contraindications (claustrophobia, implantable devices, \>550 lbs)
- • History of bleeding or clotting disorders, thrombocytopenia, warfarin and/or heparin use
- • Taking sulfonamides, procaine, thiazolsulfone or probenecid
About University Of Colorado, Denver
The University of Colorado, Denver, is a leading academic institution dedicated to advancing medical research and improving healthcare outcomes. With a strong emphasis on innovation and collaboration, the university conducts a diverse range of clinical trials aimed at addressing critical health challenges. Its research initiatives are supported by a multidisciplinary team of experts, state-of-the-art facilities, and a commitment to ethical standards and patient safety. By fostering partnerships with local and global communities, the University of Colorado, Denver, strives to translate scientific discoveries into meaningful advancements in clinical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aurora, Colorado, United States
Patients applied
Trial Officials
Petter Bjornstad, MD
Principal Investigator
Children's Hospital Colorado
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials